These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25011422)

  • 81. Recurrent varicella following steroids and fingolimod in a Multiple Sclerosis patient.
    Ferraro D; De Biasi S; Vitetta F; Simone AM; Federzoni L; Borghi V; Cossarizza A; Nichelli PF; Sola P
    J Neuroimmune Pharmacol; 2013 Dec; 8(5):1059-61. PubMed ID: 24163092
    [No Abstract]   [Full Text] [Related]  

  • 82. Fingolimod for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
    Algahtani H; Shirah B; Al Malik Y; Meftah I
    Clin Neuropharmacol; 2020; 43(2):35-38. PubMed ID: 32106137
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.
    Arvin AM; Wolinsky JS; Kappos L; Morris MI; Reder AT; Tornatore C; Gershon A; Gershon M; Levin MJ; Bezuidenhoudt M; Putzki N
    JAMA Neurol; 2015 Jan; 72(1):31-9. PubMed ID: 25419615
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Real-world effectiveness of fingolimod in Polish group of patients with relapsing-remitting multiple sclerosis.
    Walczak A; Kurkowska-Jastrzebska I; Zakrzewska-Pniewska B; Dorobek M; Brola W; Zajdel R; Bartosik-Psujek H; Stasiolek M; Kulakowska A; Rusek S; Tutaj A; Glabinski A; Wlodek A; Kochanowski J; Ciach A; Siger M; Kurowska K; Wicha W; Nojszewska M; Podlecka-Pietowska A; Czajka A; Kapica-Topczewska K; Bielecki B; Maciagowska-Terela M; Stepien A
    Clin Neurol Neurosurg; 2019 Sep; 184():105453. PubMed ID: 31376776
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E; Louapre C; Lubetzki C; Papeix C
    Mult Scler; 2014 Apr; 20(4):505-9. PubMed ID: 24367037
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study.
    Ordoñez-Boschetti L; Rey R; Cruz A; Sinha A; Reynolds T; Frider N; Alvarenga R
    Adv Ther; 2015 Jul; 32(7):626-35. PubMed ID: 26170105
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.
    Cohen M; Maillart E; Tourbah A; De Sèze J; Vukusic S; Brassat D; Anne O; Wiertlewski S; Camu W; Courtois S; Ruet A; Debouverie M; Le Page E; Casez O; Heinzlef O; Stankoff B; Bourre B; Castelnovo G; Rico A; Berger E; Camdessanche JP; Defer G; Clavelou P; Al Khedr A; Zephir H; Fromont A; Papeix C; Brochet B; Pelletier J; Lebrun C;
    JAMA Neurol; 2014 Apr; 71(4):436-41. PubMed ID: 24566807
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial.
    Laroni A; Brogi D; Morra VB; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL;
    BMC Neurol; 2014 Apr; 14():65. PubMed ID: 24690227
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Relapse of multiple sclerosis in a patient retaining CCR7-expressing T cells in CSF under fingolimod therapy.
    Yokoseki A; Saji E; Arakawa M; Hokari M; Ishiguro T; Yanagimura F; Ishihara T; Okamoto K; Nishizawa M; Kawachi I
    Mult Scler; 2013 Aug; 19(9):1230-3. PubMed ID: 23519973
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Fingolimod after natalizumab and the risk of short-term relapse.
    Jokubaitis VG; Li V; Kalincik T; Izquierdo G; Hodgkinson S; Alroughani R; Lechner-Scott J; Lugaresi A; Duquette P; Girard M; Barnett M; Grand'Maison F; Trojano M; Slee M; Giuliani G; Shaw C; Boz C; Spitaleri DL; Verheul F; Haartsen J; Liew D; Butzkueven H;
    Neurology; 2014 Apr; 82(14):1204-11. PubMed ID: 24610329
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis.
    Kappos L; Radue EW; Chin P; Ritter S; Tomic D; Lublin F
    J Neurol; 2016 Feb; 263(2):354-360. PubMed ID: 26645392
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Vagomimetic effects of fingolimod: physiology and clinical implications.
    Vanoli E; Pentimalli F; Botto G
    CNS Neurosci Ther; 2014 Jun; 20(6):496-502. PubMed ID: 24836740
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.
    Huggins A; Sergott RC
    Curr Opin Ophthalmol; 2011 Nov; 22(6):447-50. PubMed ID: 21946305
    [No Abstract]   [Full Text] [Related]  

  • 94. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.
    Izquierdo G; O'Connor P; Montalban X; von Rosenstiel P; Cremer M; de Vera A; Sfikas N; Francis G; Radue EW; Kappos L
    Mult Scler; 2014 Jun; 20(7):877-81. PubMed ID: 24293455
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Clinical pharmacokinetics of fingolimod.
    David OJ; Kovarik JM; Schmouder RL
    Clin Pharmacokinet; 2012 Jan; 51(1):15-28. PubMed ID: 22149256
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A Prospective, Observational Study Assessing Effectiveness, Safety, and QoL of Greek Patients with Multiple Sclerosis Under Treatment with Fingolimod.
    Mitsikostas DD; Orologas A; Dardiotis E; Fakas N; Doskas T; Karageorgiou K; Maltezou M; Iliopoulos I; Vikelis M; Grigoriadis N
    Adv Ther; 2023 May; 40(5):2217-2233. PubMed ID: 36897520
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis.
    Crespo C; Izquierdo G; García-Ruiz A; Granell M; Brosa M
    Neurologia; 2014 May; 29(4):210-7. PubMed ID: 24161412
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Fingolimod is a potential novel therapy for multiple sclerosis.
    Aktas O; Küry P; Kieseier B; Hartung HP
    Nat Rev Neurol; 2010 Jul; 6(7):373-82. PubMed ID: 20551946
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Effects of fingolimod in relapsing-remitting multiple sclerosis.
    Sorensen PS
    Lancet Neurol; 2014 Jun; 13(6):526-7. PubMed ID: 24685277
    [No Abstract]   [Full Text] [Related]  

  • 100. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.
    Agashivala N; Wu N; Abouzaid S; Wu Y; Kim E; Boulanger L; Brandes DW
    BMC Neurol; 2013 Oct; 13():138. PubMed ID: 24093542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.